FOCUSED
ON YOUR HEALTH



ATC Reimbursed

List of reimbursed drugs, is an important part of Service Packages covering the Fund of Compulsory Health Care Insurances for the population. The list of reimbursable drugs aims at improving the quality of service for all patients, particularly for people in need. In this regard, through the new list of drugs, FCHC aims at increasing the attention toward categories such as retirees and patients suffering from serious illnesses.

In compiling the list of drugs there are some scientific criteria which have been taken into consideration, by giving priority to drugs used for severe diseases; diseases of high risk for life; diseases that cause disability; diseases that risk of being spread into the society; diseases that cause much suffering as well as chronic illnesses requiring prolonged treatment.

Alimentary Tract And Metabolism - Reimbursed

Oral drops solution – (10.000 UI + 10.000 UI) / ml

Solution for injection - (0.1%) 1 mg/1 ml

Sugar coated tablets - 10 mg

Buskolamin contains as active substance hyoscine butylbromide. Hyoscine butylbromide is a quaternary ammonium salt. This drug, due to its anticholinergic action, possesses antispasmodic properties and it is used to relieve smooth muscle spasms.

Buskolamin 10 mg sugar-coated tablets are indicated in:

  • gastrointestinal or genitourinary spasms;
  • Irritable Bowel Syndrome.

 

Tablets - 5 mg

Tablets - 500 mg

Metformine is an oral antidiabetic which is not chemically or pharmacologically related to sulfonylurea derivatives. Metformine improves glucose tolerance in non-insulin-dependent diabetes mellitus by reducing basal and after-meal blood glucose levels. Metformine also reduces hepatic glucose production, intestinal glucose absorption and improves insulin sensitivity (increases peripheral glucose uptake).

Metformine is indicated in non-insulin-dependent diabetes mellitus when treatment by diet modification alone has not been effective and when the patient is overweight. Metformine may be used alone as initial treatment or in combination with a sulfonylurea derivative.

In insulin-dependent diabetes mellitus, Metformine may be used as adjunctive treatment in patients whose symptoms are difficult to manage.

Tablets - 850 mg

Metformine is an oral antidiabetic which is not chemically or pharmacologically related to sulfonylurea derivatives. Metformine improves glucose tolerance in non-insulin-dependent diabetes mellitus by reducing basal and after-meal blood glucose levels. Metformine also reduces hepatic glucose production, intestinal glucose absorption and improves insulin sensitivity (increases peripheral glucose uptake).

Metformine is indicated in non-insulin-dependent diabetes mellitus when treatment by diet modification alone has not been effective and when the patient is overweight. Metformine may be used alone as initial treatment or in combination with a sulfonylurea derivative.

In insulin-dependent diabetes mellitus, Metformine may be used as adjunctive treatment in patients whose symptoms are difficult to manage.

Film-coated tablets - 1000 mg

Metformine is an oral antidiabetic which is not chemically or pharmacologically related to sulfonylurea derivatives. Metformine improves glucose tolerance in non-insulin-dependent diabetes mellitus by reducing basal and after-meal blood glucose levels. Metformine also reduces hepatic glucose production, intestinal glucose absorption and improves insulin sensitivity (increases peripheral glucose uptake).

Metformine is indicated in non-insulin-dependent diabetes mellitus when treatment by diet modification alone has not been effective and when the patient is overweight. Metformine may be used alone as initial treatment or in combination with a sulfonylurea derivative.

In insulin-dependent diabetes mellitus, Metformine may be used as adjunctive treatment in patients whose symptoms are difficult to manage.

Tablets - 200 mg

Nicotinamide and nicotinic acid (vitamin PP), are water-soluble vitamin B substances. They are converted in organism to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). These two products are important coenzymes which are involved in the respiratory chain.

Nicotinic acid deficiency develops when the dietary intake is inadequate. Deficiency leads to the development of a syndrome known as pellagra, characterized by skin lesions, especially on areas exposed to sunlight, with hyperpigmentation and hyperkeratinisation. Other symptoms include diarrhoea, abdominal pain, glossitis, stomatitis, loss of appetite, headache, lethargy, and mental and neurological disturbances.

It is indicated in:

  • cases of increased needs for nicotinamide, eg. during pregnancy and breastfeeding;
  • debilitated persons and diabetic persons;
  • a range of organic and functional diseases of the brain blood vessels (obliterating atherosclerosis, cerebral embolism, spastic migraine);
  • organic peripheral vascular disease (Morbus Buerger);
  • functional peripheral vascular disease as Raynaud’s disease, acrocyanosis;
  • infectious diseases, metabolic disorders, allergies, anorexia, vomiting;
  • ophthalmology; used in burns of conjunctiva and cornea from the heat of chemical substances, in diseases of fundus oculi and optic nerve due to vascular diseases;
  • otorhinolaryngology; indicated in spastic damage of hearing and vestibular damage;
  • stomatitis, glossitis, gingivitis, aphthae;
  • dermatology; used in eczema, frostbite, toxic dermatitis, alopecia areata.

 

Solution for injection - (4%) 40 mg/1 ml

Film – coated tablets – 500.000 IU

Film – coated tablets – 500.000 IU

Gastroresistant capsules - 20 mg

 

Solution for injection - 50 mg / ml

 

Solution for injection - 100 mg / 2 ml

 

Solution for injection - (5%) 100 mg/2 ml

Results 1 - 15 of 15